Inhibitors of hepatitis C virus

1. A compound of formula (I):

wherein:

R 1 is selected from C 1-6 alkyl, phenyl, C 3-6 cycloalkyl, heteroaryl, and heterocycle; wherein C 1-6 alkyl is optionally substituted with —OR q , wherein R q is hydrogen or C 1-3 alkyl;

R 2 is selected from hydrogen and C 1-6 alkyl;

R 3 is selected from hydrogen, C 1-6 alkyl, —C(O)OC 1-6 alkyl,—C(O)OC 3-6 cycloalkyl, —C(O)NR a R b , —C(O)C 1-6 alkyl, —C(O)C 3-6 cycloalkyl, and —S(O) 2 C 1-3 alkyl;

wherein

R a and R b are independently hydrogen or C 1-6 alkyl;

R 4 is —C(O)R 5 or —S(O) 2 R 6 ;

R 5 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, —C(R k R d )NR e R f , —NR g R h , heteroaryl, heterocycle, —CH 2 -heteroaryl, and phenyl;

wherein

C 1-6 alkyl is optionally substituted with one or two substituents independently selected from —OR c , —S(O) 2 C 1-3 alkyl, —NHC(O)C 1-3 alkyl, and —NHC(O)OC 1-3 alkyl;

C 1-6 alkoxy is optionally substituted with —OR d ;

C 3-6 cycloalkyl is optionally substituted with one, two, or three substituents independently selected from C 1-3 alkyl, NR j R m , —OR n , and halo;

any heterocycle is optionally substituted with one, two, or three substituents independently selected from C 1-3 alkyl, halo, —C(O)OC 1-3 alkyl, —C(O)C 1-6 alkyl, —C(O)C 3-6 cycloalkyl, —C(O)NHC 1-6 alkyl, —C(O)NHC 3-6 cycloalkyl, and —S(O) 2 C 1-3 alkyl;

wherein any —C(O)C 1-6 alkyl is optionally substituted with —NHC(O)OC 1-3 alkyl, —OR n , —NR d R e , or heterocycle,

any —C(O)C 3-6 cycloalkyl is optionally substituted with one or two C 1-3 alkyl, and

any —C(O)NHC 1-6 alkyl is optionally substituted with —OR n or C 3-6 cycloalkyl;

any heteroaryl is optionally substituted with C 1-6 alkyl or halo;

R c is independently selected from hydrogen, C 1-6 alkyl, and phenyl;

R d is independently hydrogen or C 1-6 alkyl;

R e is independently hydrogen or C 1-6 alkyl;

R f is independently selected from hydrogen, C 1-6 alkyl, —C(O)OC 1-6 alkyl, and —C(O)C 1-6 alkyl;

R n is independently hydrogen or C 1-3 alkyl;

R k is independently selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, and —CH 2 OR n ;

R g is independently hydrogen or C 1-6 alkyl;

R h is independently selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, and —S(O) 2 C 1-3 alkyl, wherein C 1-6 alkyl is optionally substituted with —OR d ;

R j is independently hydrogen or C 1-6 alkyl;

R m is independently selected from hydrogen, C 1-6 alkyl, —C(O)OC 1-6 alkyl, and —C(O)C 1-6 alkyl;

R 6 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, and a heteroaryl ring;

R 7 , R 8 , and R 11 are independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, —C(O)OR n , —CH 2 NR a R b , and —CN, wherein C 1-6 alkyl and C 1-6 alkoxy are optionally substituted with one, two, three, four, or five halo, and wherein C 1-6 alkoxy is optionally substituted with —OR d ;

R 9 is independently selected from C 1-6 alkyl, —CH 2 OR n , —C(O)NR n R p , and C(O)OR n , wherein C 1-6 alkyl is optionally substituted with —S(O) 2 C 1-3 alkyl or with —SC 1-3 alkyl;

R p is independently hydrogen or C 1-3 alkyl;

R 10 is selected from hydrogen, halo, C 1-6 alkyl, —C(O)OR c , —C(O)NR a R b , —CH 2 NR a R b , C 3-6 cycloalkyl, and —CN;

W′, X′, Y′, and Z′ are each carbon wherein each carbon atom is bonded to hydrogen or to R 11 ;

W, X, Y, and Z are each carbon wherein each carbon atom is bonded to hydrogen or to R 7 ;

A m is —NHC(O);

Q, U, and V are each carbon wherein each carbon atom is bonded to hydrogen or to R 8 ,

T is nitrogen; and

a, b, c, and d are independently 0, 1, or 2;

or a pharmaceutically-acceptable salt or stereoisomer thereof.

2. The compound of claim 1 wherein:

R 5 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, —C(R k R d )NR e R f , —NR g R h , heteroaryl, heterocycle, —CH 2 -heteroaryl, and phenyl;

wherein

C 1-6 alkyl is optionally substituted with —OR c or —S(O) 2 C 1-3 alkyl;

C 3-6 cycloalkyl is optionally substituted with one or two C 1-3 alkyl, or with NR j R m or —OR n ;

any heterocycle is optionally substituted with one or two substituents selected from C 1-3 alkyl, halo, —C(O)OC 1-3 alkyl, —C(O)C 1-6 alkyl, and —C(O)C 3-6 cycloalkyl,

wherein —C(O)C 1-6 alkyl is optionally substituted with —NHC(O)OC 1-3 alkyl, and

—C(O)C 3-6 cycloalkyl is optionally substituted with one or two C 1-3 alkyl;

any heteroaryl is optionally substituted with C 1-6 alkyl;

R h is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, and —S(O) 2 C 1-3 alkyl;

R 6 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, and a heteroaryl ring; and

R 7 , R 8 , and R 11 are independently selected from halo, C 1-6 alkyl, C 1-6 alkoxy, —C(O)OR n , —CH 2 NR a R b , and —CN, wherein C 1-6 alkyl and C 1-6 alkoxy are optionally substituted with one, two, or three halo.

3. The compound of claim 2 wherein:

R 1 is selected from C 1-6 alkyl, phenyl, and C 3-6 cycloalkyl, wherein C 1-6 alkyl is optionally substituted with —OR q ;

R 3 is selected from hydrogen, C 1-6 alkyl, —C(O)OC 1-6 alkyl, —C(O)NR a R b , —C(O)C 3-6 cycloalkyl, and —S(O) 2 C 1-3 alkyl; and

R 10 is selected from hydrogen, halo, and C 1-6 alkyl.

4. The compound of claim 3 wherein the compound is a compound of formula (II):

wherein

R 5 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, —C(R k R d )NR e R f , —NR g R h , heteroaryl, heterocycle, and —CH 2 -heteroaryl;

wherein

any heteroaryl or heterocycle has five or six ring atoms;

C 3-6 cycloalkyl is optionally substituted with one or two C 1-3 alkyl;

any heterocycle is optionally substituted with one or two substituents selected from C 1-3 alkyl, halo, —C(O)OC 1-3 alkyl, —C(O)C 1-6 alkyl, and —C(O)C 3-6 cycloalkyl,

wherein —C(O)C 1-6 alkyl is optionally substituted with —NHC(O)OC 1-3 alkyl, and

—C(O)C 3-6 cycloakyl is optionally substituted with one or two

C 1-3 alkyl;

R k , R d , R e , R g , and R h are each independently hydrogen or C 1-3 alkyl;

R f is selected from hydrogen and —C(O)C 1-3 alkyl;

R 7 is selected from halo, C 1-6 alkyl, and C 1-6 alkoxy wherein C 1-6 alkyl and C 1-6 alkoxy are optionally substituted with one, two, or three halo;

R 9 is C 1-3 alkyl or —CH 2 OR n ; and

T is N.

5. The compound of claim 4 wherein T is N.

6. The compound of claim 4 wherein R 1 is isopropyl; R 2 is hydrogen; and R 3 is —C(O)OCH 3 .

7. The compound of claim 4 wherein R 5 is selected from, —O-tert-butyl, cyclopropyl, tert-butyl, —NHCH 3 , 2,2-dimethylcyclopropyl, pyrimidinyl, pyrazolyl, imidazolyl, —CH 2 -pyrazolyl, 1-acetylpyrrolidinyl.

8. The compound of claim 1 wherein the compound of formula (I) is a compound of formula (III):

wherein

R 1 is selected from C 1-6 alkyl, phenyl, and C 3-6 cycloalkyl, wherein C 1-6 alkyl is optionally substituted with —OR q ;

R 3 is selected from hydrogen, C 1-6 alkyl, —C(O)OC 1-6 alkyl, —C(O)NR a R b , —C(O)C 3-6 cycloallyl, and —S(O) 2 C 1-3 alkyl;

R 5 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, —C(R k R d )NR e R f , —NR g R h , heteroaryl, heterocycle, and —CH 2 -heteroaryl;

wherein:

any heteroaryl or heterocycle has 5 or 6 ring atoms;

C 1-6 alkyl is optionally substituted with one or two substituents independently selected from —OR c , —NHC(O)C 1-3 alkyl, and —NHC(O)OC 1-3 alkyl;

C 1-6 alkoxy is optionally substituted with —OR d ;

C 3-6 cycloalkyl is optionally substituted with one or two substituents independently selected from C 1-3 alkyl and halo;

any heterocycle is optionally substituted with one, two, or three substituents independently selected from C 1-3 alkyl, halo, —C(O)OC 1-3 alkyl, —C(O)C 1-6 alkyl, —C(O)C 3-6 cycloalkyl, —C(O)NHC 1-6 alkyl, and —C(O)NHC 3-6 cycloalkyl;

wherein any —C(O)C 1-6 alkyl is optionally substituted with —NHC(O)OC 1-3 alkyl, —OR n , —NR d R e , or heterocycle,

any —C(O)C 3-6 cycloalkyl is optionally substituted with one or two C 1-3 alkyl, and

any —C(O)NHC 1-6 alkyl is optionally substituted with —OR n or C 3-6 cycloalkyl;

any heteroaryl is optionally substituted with C 1-3 alkyl;

R k , R d , R e , R g , and R h are each independently hydrogen or C 1-3 alkyl;

R f is selected from hydrogen and —C(O)C 1-3 alkyl;

R 7 is selected from halo, C 1-3 alkyl, and C 1-3 alkoxy wherein C 1-3 alkyl, and C 1-3 alkoxy are optionally substituted with one, two, or three halo; and

R 9 is C 1-3 alkyl;

a is 1 or 2; and

c is 1 or 2.

9. The compound of claim 8 wherein R 5 is selected from C 3-4 cycloalkyl, —CH 2 NR e R f , —NR g R h , imidazolyl, pyrazolyl, pyrimidinyl, and pyrrolidinyl;

wherein:

C 3-4 cycloalkyl is optionally substituted with one or two C 1-3 alkyl;

pyrrolidinyl is substituted with methyl and a substituent selected from —C(O)OC 1-3 alkyl, —C(O)C 1-6 alkyl, and —C(O)NHC 1-6 alkyl, wherein

—C(O)C 1-6 alkyl is substituted with —NHC(O)OC 1-3 alkyl, —OR n , —NR d R e , or heterocycle.

10. The compound of claim 8 , wherein R 5 is selected from —NHCH 3, 2,2-dimethylcyclopropyl,

11. The compound of claim 8 wherein R 1 is C 1-6 alkyl, R 2 is hydrogen; and R 3 is —C(O)OC 1-6 alkyl.

12. The compound of claim 8 wherein R 7 is selected from fluoro, chloro, —CF 3 , and —OCF 3 , and R 9 is methyl.

13. The compound of claim 8 wherein:

R 1 is isopropyl, R 2 is hydrogen; and R 3 is —C(O)OCH 3 ;

R 7 is selected from fluoro, chloro, —CF 3 , and —OCF 3 , and R 9 is methyl; and

R 5 is selected from —NHCH 3 ,2,2-dimethylcyclopropyl, and

14. The compound of claim 8 wherein the compound is selected from:

and pharmaceutically-acceptable salts thereof.

15. The compound of claim 8 wherein the compound is selected from:

and pharmaceutically-acceptable salts thereof.

16. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically-acceptable carrier.

17. The pharmaceutical composition of claim 16 further comprising one or more other therapeutic agents useful for treating hepatitis C viral infections.

18. The pharmaceutical composition of claim 17 wherein the one or more other therapeutic agents is selected from HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside polymerase inhibitors, interferons and pegylated interferons, and ribavirin and nucleoside analogs related to ribavirin.